214 related articles for article (PubMed ID: 24239470)
1. The prostate cancer genome: perspectives and potential.
Barbieri CE; Tomlins SA
Urol Oncol; 2014 Jan; 32(1):53.e15-22. PubMed ID: 24239470
[TBL] [Abstract][Full Text] [Related]
2. Reprint of: The prostate cancer genome: Perspectives and potential.
Barbieri CE; Tomlins SA
Urol Oncol; 2015 Feb; 33(2):95-102. PubMed ID: 25726356
[TBL] [Abstract][Full Text] [Related]
3. The mutational landscape of prostate cancer.
Barbieri CE; Bangma CH; Bjartell A; Catto JW; Culig Z; Grönberg H; Luo J; Visakorpi T; Rubin MA
Eur Urol; 2013 Oct; 64(4):567-76. PubMed ID: 23759327
[TBL] [Abstract][Full Text] [Related]
4. Sequencing the transcriptional network of androgen receptor in prostate cancer.
Chng KR; Cheung E
Cancer Lett; 2013 Nov; 340(2):254-60. PubMed ID: 23196061
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer: germline prediction for a commonly variable malignancy.
Bambury RM; Gallagher DJ
BJU Int; 2012 Dec; 110(11 Pt C):E809-18. PubMed ID: 22974436
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer genomics by high-throughput technologies: genome-wide association study and sequencing analysis.
Nakagawa H
Endocr Relat Cancer; 2013 Aug; 20(4):R171-81. PubMed ID: 23625613
[TBL] [Abstract][Full Text] [Related]
7. Molecular genetics of prostate cancer: emerging appreciation of genetic complexity.
Barbieri CE; Demichelis F; Rubin MA
Histopathology; 2012 Jan; 60(1):187-98. PubMed ID: 22212086
[TBL] [Abstract][Full Text] [Related]
8. Molecular genetics of prostate cancer: clinical translational opportunities.
Vecchione A; Gottardo F; Gomella LG; Wildemore B; Fassan Ms; Bragantini E; Pagano F; Baffa R
J Exp Clin Cancer Res; 2007 Mar; 26(1):25-37. PubMed ID: 17550130
[TBL] [Abstract][Full Text] [Related]
9. Molecular biology of prostate-cancer pathogenesis.
Shand RL; Gelmann EP
Curr Opin Urol; 2006 May; 16(3):123-31. PubMed ID: 16679847
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide methylation analysis identifies involvement of TNF-α mediated cancer pathways in prostate cancer.
Kim SJ; Kelly WK; Fu A; Haines K; Hoffman A; Zheng T; Zhu Y
Cancer Lett; 2011 Mar; 302(1):47-53. PubMed ID: 21237555
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathology and prostate cancer therapeutics: from biology to bedside.
Rodrigues DN; Butler LM; Estelles DL; de Bono JS
J Pathol; 2014 Jan; 232(2):178-84. PubMed ID: 24108540
[TBL] [Abstract][Full Text] [Related]
12. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
Chung LW; Baseman A; Assikis V; Zhau HE
J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic biomarkers in prostate cancer: Current and future uses.
Chiam K; Ricciardelli C; Bianco-Miotto T
Cancer Lett; 2014 Jan; 342(2):248-56. PubMed ID: 22391123
[TBL] [Abstract][Full Text] [Related]
14. Environmental, genetic, and molecular features of prostate cancer.
Deutsch E; Maggiorella L; Eschwege P; Bourhis J; Soria JC; Abdulkarim B
Lancet Oncol; 2004 May; 5(5):303-13. PubMed ID: 15120667
[TBL] [Abstract][Full Text] [Related]
15. Genomic analysis in active surveillance: predicting high-risk disease using tissue biomarkers.
Donovan MJ; Cordon-Cardo C
Curr Opin Urol; 2014 May; 24(3):303-10. PubMed ID: 24625431
[TBL] [Abstract][Full Text] [Related]
16. ETS gene fusions in prostate cancer: from discovery to daily clinical practice.
Tomlins SA; Bjartell A; Chinnaiyan AM; Jenster G; Nam RK; Rubin MA; Schalken JA
Eur Urol; 2009 Aug; 56(2):275-86. PubMed ID: 19409690
[TBL] [Abstract][Full Text] [Related]
17. Genomic approaches to outcome prediction in prostate cancer.
Febbo PG
Cancer; 2009 Jul; 115(13 Suppl):3046-57. PubMed ID: 19544546
[TBL] [Abstract][Full Text] [Related]
18. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
Dobosy JR; Roberts JL; Fu VX; Jarrard DF
J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
[TBL] [Abstract][Full Text] [Related]
19. Molecular markers in the diagnosis of prostate cancer.
van der Poel HG
Crit Rev Oncol Hematol; 2007 Feb; 61(2):104-39. PubMed ID: 16945550
[TBL] [Abstract][Full Text] [Related]
20. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications.
Shah RB; Chinnaiyan AM
Adv Anat Pathol; 2009 May; 16(3):145-53. PubMed ID: 19395877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
